Share on LinkedInShare on LinkedIn

ARTICLE · 21 OCTOBER 2020

The TGA early notice scheme for patentees: Not yet safe or effective

Corrs Chambers Westgarth
Corrs Chambers Westgarth
Contributor
Corrs Chambers Westgarth

Corrs Chambers Westgarth

Corrs Chambers Westgarth is Australia’s leading independent law firm. We provide exceptional legal...

View firm profile
Explore more from Corrs Chambers Westgarth

The proposed approach does not provide transparency as to which patents are relevant to particular therapeutic products.

AustraliaIntellectual Property

Earlier this year, we reported on proposals by Australia's Therapeutic Goods Administration (TGA) to: 

  • release certain information about applications for the registration of new medicines shortly after preliminary assessment; and 

  • require generic or biosimilar pharmaceutical companies to notify innovator companies when making applications to register generic or biosimilar pharmaceutical products.

On 9 October 2020, the TGA announced that the Federal Government has given approval for both measures to be implemented. The first measure (publication of new medicines) will commence from January 2021. Legislative changes to implement the second measure (the notice scheme for generic / biosimilar companies) will be introduced to Parliament in “late 2020”. The TGA has previously indicated that the second measure would be implemented in “early 2021”.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

    Lawyers Weekly Law firm of the year 2021                  
Employer of Choice for Gender Equality (WGEA)

See more popular content from